Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients With Hepatocellular Carcinoma
- To determine the safety of hypofractionated stereotactic radiotherapy (SRT) in patients
with advanced hepatocellular carcinoma.
- To determine the maximum tolerated dose of SRT in these patients.
- To determine the objective tumor response rate in terms of the percentage of tumor size
change on CT, percentage of intensity change on MRI, and the percentage of change in
alfa fetoprotein in patients treated with this therapy.
- To determine the value of 4-dimensional CT in liver cancer planning in terms of the
extent of liver motion (three dimensionally) and the percentage of patients requiring
breath gating due to the amplitude of organ motion exceeding 1 cm in any dimension.
- To determine the value of breath gating in liver cancer SRT in terms of the success
rate of breath gating and the percentage of treatment time prolongation secondary to
OUTLINE: Patients undergo hypofractionated stereotactic radiotherapy once daily on days 1-5.
After completion of study therapy, patients are followed at 1 and 3 months.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity as assessed by NCI CTCAE v3.0
Up to 1 month after SRT
Chi Lin, MD, PhD
University of Nebraska
United States: Institutional Review Board
|UNMC Eppley Cancer Center at the University of Nebraska Medical Center||Omaha, Nebraska 68198-7680|